Bøger i Handbook of Experimental Pharmacology serien

This volume connects current ideas and concepts about sleep functions and circadian rhythms with the search for novel target-selective sleep-wake therapeutics. To do so, it provides a timely, state-of-the-art overview of sleep-wake mechanisms in health and disease, ongoing developments in drug discovery, and their prospects for the clinical treatment of sleep-disordered patients. It particularly focuses on the concept that sleep and wakefulness mutually affect each other, and the future therapeutic interventions with either sleep- or wake-promoting agents that are expected to not only improve the quality of sleep but also the waking behavior, cognition, mood and other sleep-associated physiological functions.The chapter 'Sleep Physiology, Circadian Rhythms, Waking Performance and the Development of Sleep-Wake Therapeutics' available open access under a CC BY 4.0 license at link.springer.com

There is currently considerable interest in the development of medicines that would enhance endocannabinoid-induced "autoprotection", for example through inhibition of endocannabinoid metabolizing enzymes or cellular uptake processes or that would oppose endocannabinoid-induced "autoimpairment".

Among the topics discussed are the structural basis of Na+ channel function, methodological advances in the study of Na+ channels, their pathophysiology and drugs and toxins interactions with these channels and their associated channelopathies.

In this context, metabolic control is highlighted at various levels of complexity ranging from transcriptional mechanisms in metabolic pathway control over metabolic communication routes in physiology and pathophysiology to current treatment modalities and options in metabolic disorders, including type 2 diabetes and obesity.

Latest research on Adhesion GPCRs has unearthed surprising revelations about the events that govern the signal transduction of these receptor molecules and the cellular and organ requirements for these signals.

In this book on "The Actin Cytoskeleton", twelve internationally renowned authors present specific chapters that cover their recent work concerned with the various roles of actin mentioned above.

This book highlights the important role free fatty acids (FFA) play as potential drug targets. While FFA have long been considered byproducts of cell metabolism, they are now recognized as ligands that regulate cell and tissue function via G-protein-coupled receptors.

Internationally recognized authorities review the most important new information on the advances in our understanding of the pathogenesis and treatment of these diseases, including the substantial advances in the topical delivery of inhaled medicines.

There have been major advancements in the pharmacologic treatment of eye diseases over the past decade. This volume will cover the pharmacologic treatment of eye diseases from the front of the eye including eyelids, conjunctiva and cornea all the way back to the retina and optic nerve.

This special issue of the Handbook of Experimental Pharmacology on Heart Failure covers the entire spectrum of the field, from the current understanding and definitions of heart failure, to epidemiology and the importance of co-morbidities, clinical trial design and biomarkers, as well as imaging technologies.

This volume reviews the known neurobiology of depression and combines classic data on antidepressant treatments with modern theory on the physiology of depression. It also discusses novel mechanism of action drugs.

This special book is conceived to highlight mitochondrial structural and functional integrity and how they are associated with several human diseases such as cardiovascular, cancer, renal, neurological disorder, and genetic disorders.

Two sigma receptor subtypes have been proposed, sigma1 and 2. Largely based on traditional pharmacologic approaches, the Sigma1 protein has been associated with a broad range of signaling systems, including G-protein coupled receptors, NMDA receptors, and ion channels.

The most voluminous part is the chapter dealing with the systemic pharma cology of these agents analyzing the effects on the central nervous system, on the autonomic nervous system, on the cardiovascular, the respiratory, the digestive, the endocrine system, on the skeletal muscle, and on metabolism.

The aim of this book is not only to introduce readers with a broad spectrum of biological actions of the NOP receptor, but also to feature a detailed look at the N/OFQ-NOP receptor system, medicinal chemistry, pharmacology, and clinical data of NOP-targeted ligands.

Further attention is paid to the drug discovery pathway where recent findings show the beneficial effect of small molecule antagonists of the CGRP receptors for the relief of the migraine attack and of monoclonal antibodies against CGRP or the CGRP receptor for migraine prevention.

This book focusses on the latest results related to the field of bile acids as signaling molecules and describes how these receptors have become a major pharmacological target.

Towards this goal, authors provide a timely state-of-the-art overview of the GI tract in health and disease, current treatment approaches and ongoing developments in drug discovery, and their potential for the better treatment of patients with GI disorders.

Lastly, the book will present important methodological aspects ranging from mass-spectrometric methods for cyclic nucleotide detection to the synthesis of nucleotide analogs as experimental tools and holistic methods for analysis of cyclic nucleotide effects.

This volume describes our current understanding of the biological role of the delta-opioid receptor (DOR) system, focusing on its unique mechanisms of receptor trafficking and signaling in disease states. Part 1 covers the endogenous ligands that regulate the DOR system as well as novel compounds and therapies used to modulate the DOR system.

Among the topics discussed are the structural basis of Na+ channel function, methodological advances in the study of Na+ channels, their pathophysiology and drugs and toxins interactions with these channels and their associated channelopathies.

Celebrating 100 years of HEP, this volume will discuss key pharmacological discoveries and concepts of the past 100 years. These discoveries have dramatically changed the medical treatment paradigms of many diseases and these concepts have and will continue to shape discovery of new medicinies.

This open access book, published under a CC BY 4.0 license in the Pubmed indexed book series Handbook of Experimental Pharmacology, provides up-to-date information on best practice to improve experimental design and quality of research in non-clinical pharmacology and biomedicine.

The aim of this book is not only to introduce readers with a broad spectrum of biological actions of the NOP receptor, but also to feature a detailed look at the N/OFQ-NOP receptor system, medicinal chemistry, pharmacology, and clinical data of NOP-targeted ligands.

Lipids are an integral part of cell membrane architecture, are intermediaries in cell metabolism, and are involved in transmitting cell signals from hormones, growth factors and nutrients.

Further attention is paid to the drug discovery pathway where recent findings show the beneficial effect of small molecule antagonists of the CGRP receptors for the relief of the migraine attack and of monoclonal antibodies against CGRP or the CGRP receptor for migraine prevention.

This open access book, published under a CC BY 4.0 license in the Pubmed indexed book series Handbook of Experimental Pharmacology, provides up-to-date information on best practice to improve experimental design and quality of research in non-clinical pharmacology and biomedicine.